Cargando…

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%

We report the first 5-year follow-up of any first-line phase III immunotherapy trial for non–small-cell lung cancer (NSCLC). KEYNOTE-024 (ClinicalTrials.gov identifier: NCT02142738) is an open-label, randomized controlled trial of pembrolizumab compared with platinum-based chemotherapy in patients w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reck, Martin, Rodríguez-Abreu, Delvys, Robinson, Andrew G., Hui, Rina, Csőszi, Tibor, Fülöp, Andrea, Gottfried, Maya, Peled, Nir, Tafreshi, Ali, Cuffe, Sinead, O'Brien, Mary, Rao, Suman, Hotta, Katsuyuki, Leal, Ticiana A., Riess, Jonathan W., Jensen, Erin, Zhao, Bin, Pietanza, M. Catherine, Brahmer, Julie R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2021
Materias:	RAPID COMMUNICATIONS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8280089/ https://www.ncbi.nlm.nih.gov/pubmed/33872070 http://dx.doi.org/10.1200/JCO.21.00174

Ejemplares similares

Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study
por: Garassino, Marina C., et al.
Publicado: (2023)

Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC
por: Kim, Hye Ryun, et al.
Publicado: (2023)

Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma
por: Li, Xin, et al.
Publicado: (2018)

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
por: Finn, Richard S., et al.
Publicado: (2020)

Murine cancer cachexia models replicate elevated catabolic pembrolizumab clearance in humans
por: Castillo, Alyssa Marie M., et al.
Publicado: (2021)

Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC
por: Garassino, Marina C., et al.
Publicado: (2022)

Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study
por: Garon, Edward B., et al.
Publicado: (2019)

Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164
por: Le, Dung T., et al.
Publicado: (2020)

Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020
por: Mizumoto, Kenji, et al.
Publicado: (2020)

Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non–Small-Cell Lung Cancer Previously Treated With Immunotherapy—Lung-MAP S1800A
por: Reckamp, Karen L., et al.
Publicado: (2022)

Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227
por: Brahmer, Julie R., et al.
Publicado: (2023)

First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRAS(G12C) Solid Tumors (KRYSTAL-1)
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2022)

Temporal rise in the proportion of younger adults and older adolescents among coronavirus disease (COVID-19) cases following the introduction of physical distancing measures, Germany, March to April 2020
por: Goldstein, Edward, et al.
Publicado: (2020)

Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042
por: Mansfield, Aaron S., et al.
Publicado: (2021)

Allele Loss on Chromosome 11 in a Pituitary Tumor from a Patient with Multiple Endocrine Neoplasia Type 1
por: Yoshimoto, Katsuhiko, et al.
Publicado: (1991)

Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non–small cell lung cancer without tumor PD‐L1 expression: A pooled analysis of 3 randomized controlled trials
por: Borghaei, Hossein, et al.
Publicado: (2020)

Counterfactual thinking in patients with amnesia
por: Mullally, Sinéad L, et al.
Publicado: (2014)

Detection of PML/Retinoic Acid Receptor α Gene Rearrangements by Polymerase Chain Reaction Using Genomic DNA in Patients with Acute Promyelocytic Leukemia
por: Tashiro, Satoshi, et al.
Publicado: (1993)

Cross-border outbreak of Yersinia enterocolitica O3 associated with imported fresh spinach, Sweden and Denmark, March 2019
por: Espenhain, Laura, et al.
Publicado: (2019)

Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study
por: Novello, Silvia, et al.
Publicado: (2023)

Odorant Receptor from the Southern House Mosquito Narrowly Tuned to the Oviposition Attractant Skatole
por: Hughes, David T., et al.
Publicado: (2010)

Characterizing memory loss in patients with autoimmune limbic encephalitis hippocampal lesions
por: Lad, Meher, et al.
Publicado: (2019)

Long-Term Real-World Outcomes of First-Line Pembrolizumab Monotherapy for Metastatic Non-Small Cell Lung Cancer With ≥50% Expression of Programmed Cell Death-Ligand 1
por: Velcheti, Vamsidhar, et al.
Publicado: (2022)

Knockdown of a Mosquito Odorant-binding Protein Involved in the Sensitive Detection of Oviposition Attractants
por: Pelletier, Julien, et al.
Publicado: (2010)

COVID-19 genome surveillance at international airport quarantine stations in Japan
por: Sekizuka, Tsuyoshi, et al.
Publicado: (2020)

Real-World Time on Treatment with First-Line Pembrolizumab Monotherapy for Advanced NSCLC with PD-L1 Expression ≥ 50%: 3-Year Follow-Up Data
por: Velcheti, Vamsidhar, et al.
Publicado: (2022)

Rapid Response to the Combination of Lenvatinib and Pembrolizumab in Patients with Advanced Carcinomas (Lung Adenocarcinoma and Malignant Pleural Mesothelioma)
por: Shalata, Walid, et al.
Publicado: (2021)

Outcome of early-stage combination treatment with favipiravir and methylprednisolone for severe COVID-19 pneumonia: A report of 11 cases
por: Murohashi, Kota, et al.
Publicado: (2020)

Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab
por: Morita, Mitsunori, et al.
Publicado: (2020)

Q-TWiST Analysis to Assess Benefit–Risk of Pembrolizumab in Patients with PD-L1–Positive Advanced or Metastatic Non-small Cell Lung Cancer
por: Huang, Min, et al.
Publicado: (2018)

Limited increase in antibody titers following mRNA SARS-CoV-2 vaccination for more than 3 years after final dose of anti-CD20 antibody
por: Funakoshi, Yohei, et al.
Publicado: (2022)

The SARS-CoV-2 Lambda variant and its neutralisation efficiency following vaccination with Comirnaty, Israel, April to June 2021
por: Zuckerman, Neta, et al.
Publicado: (2021)

Pemetrexed and Platinum Plus Pembrolizumab in Patients With Metastatic Nonsquamous NSCLC by Tumor Burden at Baseline: A Post Hoc Efficacy Analysis of KEYNOTE-189
por: Gadgeel, Shirish, et al.
Publicado: (2022)

Monkeypox DNA levels correlate with virus infectivity in clinical samples, Israel, 2022
por: Paran, Nir, et al.
Publicado: (2022)

Serial liquid biopsies for detection of treatment failure and profiling of resistance mechanisms in KLC1–ALK-rearranged lung cancer
por: Dietz, Steffen, et al.
Publicado: (2019)

Measles outbreak: preliminary report on a case series of the first 8,070 suspected cases, Manaus, Amazonas state, Brazil, February to November 2018
por: Elidio, Guilherme Almeida, et al.
Publicado: (2019)

Efficacy and Safety of Pembrolizumab in Patients with Refractory Advanced Biliary Tract Cancer: Tumor Proportion Score as a Potential Biomarker for Response
por: Kang, Junho, et al.
Publicado: (2020)

Pembrolizumab
por: Khoja, Leila, et al.
Publicado: (2015)

Some features of large multiwire proportional chambers
por: Charpak, Georges, et al.
Publicado: (1971)

Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021
por: Kissling, Esther, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kcmq1aika8imhff434o25d1sua